BiotechTube

Bel-sar

Phase 3Recruiting
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Choroidal Melanoma

Conditions

Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma

Trial Timeline

Dec 6, 2023 → Aug 15, 2028

NCT ID
NCT06007690

About Bel-sar

Bel-sar is a phase 3 stage product being developed by Aura Biosciences for Choroidal Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06007690. Target conditions include Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma.

What happened to similar drugs?

7 of 15 similar drugs in Choroidal Melanoma were approved

Approved (7) Terminated (0) Active (8)
✅Verteporfin Photodynamic Therapy + RanibizumabNovartisApproved
✅ranibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅Intravitreal aflibercept injection 2.0mgRegeneron PharmaceuticalsApproved
✅Rescue Intravitreal Aflibercept InjectionRegeneron PharmaceuticalsApproved
✅Aflibercept Intravitreous InjectionBayerApproved
✅afliberceptBayerApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06007690Phase 3Recruiting

Competing Products

20 competing products in Choroidal Melanoma

See all competitors
ProductCompanyStageHype Score
Zimura + EyleaAstellas PharmaPhase 2
27
Avacincaptad PegolAstellas PharmaPhase 2
35
Verteporfin Photodynamic Therapy + RanibizumabNovartisApproved
43
ranibizumabNovartisApproved
43
RanibizumabNovartisApproved
43
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDTNovartisPhase 3
40
ranibizumabNovartisPhase 3
40
Everolimus + RanibizumabNovartisPhase 2
27
RanibizumabNovartisPhase 3
40
ranibizumab 0.5mgNovartisPhase 2
35
ranibizumabNovartisPhase 3
40
Brolucizumab 6mg + Brolucizumab 6mgNovartisPhase 3
40
Intravitreal injection ranibizumabNovartisPhase 2
35
RanibizumabNovartisPhase 3
40
RanibizumabNovartisPhase 1/2
32
Faricimab + Ranibizumab + Sham ProcedureRochePhase 2
35
Faricimab + RanibizumabRochePhase 3
44
Faricimab + Ranibizumab + Sham ProcedureRochePhase 2
35
Intravitreal PegaptanibPfizerPre-clinical
18
Intravitreal aflibercept injection 2.0mgRegeneron PharmaceuticalsApproved
43